---
title: "ALA: Off-the-shelf CAR-iNKT therapy nears first patient dosing, targeting broad oncology and autoimmune markets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295620311.md"
description: "A differentiated off-the-shelf CAR-iNKT cell therapy platform is advancing to first-in-human trials for blood cancers, with expansion plans for solid tumors and autoimmune diseases. The approach offers cost, speed, and safety advantages, with key milestones and early clinical data expected in the next 6–12 months.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T06:14:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295620311.md)
  - [en](https://longbridge.com/en/news/295620311.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295620311.md)
generator: "portal-rs"
---

# ALA: Off-the-shelf CAR-iNKT therapy nears first patient dosing, targeting broad oncology and autoimmune markets

A differentiated off-the-shelf CAR-iNKT cell therapy platform is advancing to first-in-human trials for blood cancers, with expansion plans for solid tumors and autoimmune diseases. The approach offers cost, speed, and safety advantages, with key milestones and early clinical data expected in the next 6–12 months.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ALA.US](https://longbridge.com/en/quote/ALA.US.md)

## Related News & Research

- [ALA: Advanced lead cell therapy to Phase 1 trials, narrowing net loss and maintaining strong cash reserves](https://longbridge.com/en/news/296422472.md)
- [TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy](https://longbridge.com/en/news/297773935.md)
- [BUZZ-TScan Therapeutics falls after pausing cancer trial](https://longbridge.com/en/news/297781139.md)
- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)
- [TCRX: In vivo TCR therapies for solid tumors advance to IND-enabling stage, with phase I trial set for Q4 2027](https://longbridge.com/en/news/297802700.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**